ADEWOLE OGUNDEPO: Open Payments
NPI 1689878753 · SILVER SPRING, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$978 in 43 payments from 10 companies in 2025. Trend: 2023 $17 · 2024 $842 · 2025 $978
Food & beverage: $977Education: $1
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $253 |
| Vanda Pharmaceuticals Inc. | 11 | $180 |
| ABBVIE INC. | 6 | $135 |
| Teva Pharmaceuticals USA, Inc. | 1 | $122 |
| Axsome Therapeutics, Inc. | 3 | $68 |
| Alkermes, Inc. | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Janssen Pharmaceuticals, Inc | 2 | $44 |
| E.R. Squibb & Sons, L.L.C. | 2 | $39 |
| Lundbeck LLC | 2 | $34 |
Products named: CAPLYTA, FANAPT, VRAYLAR, UZEDY, Auvelity, ARISTADA, INVEGA SUSTENNA, ABILIFY ASIMTUFII.
Industry payments across MD — which companies pay providers there.
